Boxer Capital, LLC
CIK 1465837 · last filed 2023-10-11
Boxer Capital, LLC is a corporate insider who has filed 27 SEC Form 4 insider transactions across 8 companies since 2009. The most recent filing shows the insider sold $11.2M of TNGX on Oct 11, 2023. Across all open-market trades the lifetime net is +$238.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $318.5M across reported positions. The firm reports its address in San Diego, CA. 63 SEC filings were submitted jointly with Boxer Asset Management Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$318.49M
8
27
$238.19M
Filer Profile
SUITE 300
SAN DIEGO, CA 92130
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TNGX | 13,937,092 | $22.52 | $313.86M | -$11.20M | 1 | 2023-10-11 | |
| RAIN | Director | 1,152,212 | $0.85 | $980.8K | $54.57M | 2 | 2023-05-24 |
| Odonate Therapeutics, Inc. (ODT) Delisted | Director | 4,207,086 | $1.12 | $4.71M | $133.68M | 8 | 2021-11-24 |
| PMVP | 982,708 | $1.29 | $1.27M | $85.50M | 1 | 2020-09-29 | |
| iTeos Therapeutics, Inc. (ITOS) Delisted | 10%+ Owner | 2,943,568 | $10.15 | $29.88M | $108.30M | 1 | 2020-07-29 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | 10%+ Owner | 1,765,560 | $58.70 | $103.64M | -$122.81M | 8 | 2020-01-14 |
| SLDB | 10%+ Owner | 231,551 | $10.25 | $2.37M | -$4.45M | 1 | 2019-03-28 |
| Pernix Sleep, Inc. (SOMX) Delisted | 109,561 | — | — | -$5.40M | 2 | 2009-08-28 |
Recent Filings
27 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-10-11 | TNGX | Sell (S) | −1,125,000 | -$11.20M | EDGAR |
| 2023-10-10 | TNGX | Notice (144) | −175,000 | -$1.99M | EDGAR |
| 2023-08-23 | iTeos Therapeutics, Inc. (ITOS) Delisted | Notice (144) | −225,000 | -$2.64M | EDGAR |
| 2023-05-24 | RAIN | Sell (S) | −3,980,000 | -$4.97M | EDGAR |
| 2023-05-22 | — | Notice (144) | −495,000 | -$4.92M | EDGAR |
| 2021-11-24 | Odonate Therapeutics, Inc. (ODT) Delisted | Sell (S) | −1,200,000 | -$1.87M | EDGAR |
| 2021-04-27 | RAIN | Mixed | +3,525,000 | $59.54M | EDGAR |
| 2020-12-30 | Odonate Therapeutics, Inc. (ODT) Delisted | Buy (P) | +1,200,000 | $20.59M | EDGAR |
| 2020-09-30 | Odonate Therapeutics, Inc. (ODT) Delisted | Buy (P) | +645,600 | $8.80M | EDGAR |
| 2020-09-29 | PMVP | Mixed | +11,645,365 | $85.50M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.